Chantibody Therapeutics
HOME
OUR COMPANY
  • ABOUT US
  • OUR PLATFORM
  • PUBLICATIONS
CAREER
CONTACT US
Chantibody Therapeutics
HOME
OUR COMPANY
  • ABOUT US
  • OUR PLATFORM
  • PUBLICATIONS
CAREER
CONTACT US
More
  • HOME
  • OUR COMPANY
    • ABOUT US
    • OUR PLATFORM
    • PUBLICATIONS
  • CAREER
  • CONTACT US
  • HOME
  • OUR COMPANY
    • ABOUT US
    • OUR PLATFORM
    • PUBLICATIONS
  • CAREER
  • CONTACT US

SITC 2025, CT224

CT224: A biparatopic VHH-based CDH17xCD3 T cell engager with optimized safety and efficacy for colorectal cancer

  

Downloads

SITC2025 CT224 (pdf)Download

Copyright © 2025 Chantibody Therapeutics - All Rights Reserved.

Powered by